Clinical trials: mFOLFOX6
Gastric Cancer Stage IV, Peritoneal Carcinomatosis
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Carcinomatosis, Intraperitoneal Paclitaxel, mFOLFOX6
- Trial name
- IPLUS (NCT03618758)
- Testing
- Paclitaxel, mFOLFOX6 regimen
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Seoul National University Bundang Hospital
Advanced Colorectal Cancer, Adenocarcinoma of the Colon
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
- Conditions
- Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT00707889
- Testing
- ABT-869, bevacizumab, oxaliplatin
- Where
- 46 sites in United States, Australia and 12 more
- Volunteers
- 159 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Colorectal Cancer
FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer
the aim of this study is to observe the effect of irinotecan-based regimen in patients with advanced colorectal cancer.
- Trial name
- NCT01566942
- Testing
- Oxaliplatin, Irinotecan
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
CRC
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody…
- Trial name
- NCT05239650
- Testing
- HLX07, HLX10, mFOLFOX6
- Volunteers
- 50 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer, Gastroesophageal Cancer
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer…
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Trial name
- NCT03798626
- Testing
- Gevokizumab, Bevacizumab, Modified FOLFOX6
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 167 people
- Sponsor
- Novartis Pharmaceuticals
Efficacy, Self, Safety Issues
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer
This is a prospective, multi-center, randomized controlled clinical intervention study, aiming to explore the effectiveness and safety of mfolfox6 and hlx04 regimens combined with slulimumab as first-line treatment for MSS-type…
- Conditions
- Efficacy, Self, Safety Issues, Colo-rectal Cancer
- Trial name
- NCT06491355
- Testing
- mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sir Run Run Shaw Hospital
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
- Trial name
- NCT03783936
- Testing
- Oxaliplatin, Leucovorin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ashwin Somasundaram
Colorectal Cancer
Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
Studies suggest that the addition of antiangiogenic agents to conventional therapeutic strategies, e.g., chemotherapy, radiation, or other tumor-targeting agents, will increase clinical efficacy.
- Trial name
- NCT01529164
- Testing
- Endostatins (Endostar), Oxaliplatin, Leucovorin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer, Liver Metastasis
Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers
The purpose of this study is to evaluate the safety of liver resection for metastatic, resectable lesions from colorectal cancers after systemic chemotherapy.
- Trial name
- NCT00594529
- Testing
- Surgery
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Kyoto University
Stage III Colon Cancer
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
- Trial name
- CIRCULATE-US (NCT05174169)
- Testing
- Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month
- Where
- 1,077 sites in United States, Canada and 1 more
- Volunteers
- 1,912 people
- Sponsor
- NRG Oncology
Rectal Cancer
Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer
This is a prospective, multicenter, open-label, single-arm Phase II study designed to evaluate the efficacy and safety of total neoadjuvant mFOLFOX6 combined with suvemcitug and enlonstobart in patients with MRI（Magnetic…
- Trial name
- SPARE (NCT07810114)
- Testing
- mFOLFOX6, Suvemcitug, Enlonstobart
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Rectal Cancer
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients.
- Trial name
- NCT03921684
- Testing
- Capecitabine, Radiation therapy, mFOLFOX6
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Baruch Brenner
Colon Adenocarcinoma, Rectal Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
- Trial name
- NCT06997497
- Testing
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium
- Where
- 244 sites in United States, Argentina and 27 more
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who…
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
- Trial name
- NCT00096278
- Testing
- Bevacizumab, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 2,710 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer.
- Trial name
- MOUNTAINEER-03 (NCT05253651)
- Testing
- tucatinib, trastuzumab, bevacizumab
- Where
- 366 sites in United States, Argentina and 23 more
- Volunteers
- 400 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Gastric Cancer
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
This protocol for Varlitinib is developed for the treatment of Gastric Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth…
- Trial name
- NCT03130790
- Testing
- Varlitinib, mFOLFOX6
- Where
- 16 sites in Estonia, Hong Kong and 6 more
- Volunteers
- 52 people
- Sponsor
- ASLAN Pharmaceuticals
Radiation Oncology, Rectal Cancer
Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer
Preoperative radiotherapy followed by total mesorectal excision (TME) has been recommended as the preferred treatment method for locally advanced rectal cancer.
- Trial name
- NCT03466424
- Testing
- preoperative short-course radiotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Fujian Medical University Union Hospital
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Colorectal Cancer
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and…
- Trial name
- NCT01478594
- Testing
- Tivozanib, Bevacizumab, mFOLFOX6
- Where
- 73 sites in United States, Australia and 10 more
- Volunteers
- 265 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer
- Trial name
- NCT05004441
- Testing
- Fruquintinib Combined With mFOLFOX6/FOLFIRI
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Zhou Fuxiang